Company intelligence / Profile preview

illumigyn

Ownership: Private
Development stage: Other

Overview

illumigyn has developed the first FDA-cleared remote gynecological imaging platform. Its Gynescope system enables high-resolution digital documentation of the cervix, vagina, and external genitalia for improved diagnostic accuracy. The system is commercially available with deployments in Africa, the United States, UAE, India, Singapore, South Korea and other regions[2][3][4]. Clinical results focus on enhanced early detection of cervical cancer through superior imaging rather than drug trials.

Therapeutic areas: Women's Health
Modalities: DeviceDigital health platformArtificial intelligence (AI) clinical decision support software (future development)
Industry: Medical Imaging

Partnerships

Peramare Enterprises Ltd. (Africa distribution)[2][5]Codimate (Côte d’Ivoire distribution)[7]

Beyond the preview

Go deeper on illumigyn.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on illumigyn.

Explore the full profile